ARCTICZYMES TECHNOLOGIES ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.65 NOK | +2.83% |
|
-0.42% | -43.69% |
| 05-13 | ArcticZymes Technologies ASA Announces Board Resignations | CI |
| 05-08 | ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Sales per Business
| NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Enzymes
100.0
%
| 137 | 100.0 % | 119 | 100.0 % | -13.16% |
Sales per region
| NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
United States
44.7
%
| 60 | 44.1 % | 53 | 44.7 % | -11.94% |
Lithuania
29.0
%
| 28 | 20.5 % | 35 | 29.0 % | +23.15% |
Other Countries in Europe
11.0
%
| 18 | 13.0 % | 13 | 11.0 % | -26.47% |
Germany
6.0
%
| 12 | 8.8 % | 7 | 6.0 % | -40.48% |
Rest of World
3.8
%
| 16 | 11.5 % | 5 | 3.8 % | -71.34% |
France
2.9
%
| - | - | 3 | 2.9 % | - |
Italy
2.4
%
| 3 | 1.9 % | 3 | 2.4 % | +9.83% |
Norway
0.2
%
| 0 | 0.3 % | 0 | 0.2 % | -48.86% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Akoh
CEO | Chief Executive Officer | - | 23-09-17 |
Børge Sørvoll
DFI | Director of Finance/CFO | 49 | 14-09-30 |
Darren Ellis
CTO | Chief Tech/Sci/R&D Officer | - | 22-11-30 |
| Chief Operating Officer | 56 | - | |
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 99-12-31 |
Dirk Hahneiser
SAM | Sales & Marketing | 56 | 21-12-31 |
Dino DiCamillo
SAM | Sales & Marketing | 66 | 11-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 99-12-31 |
| Chief Operating Officer | 56 | - | |
Bernd Striberny
BRD | Director/Board Member | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 50,871,390 | 35,904,791 ( 70.58 %) | 0 | 70.58 % |
Company contact information
ArcticZymes Technologies ASA
Siva Innovasjonssenter Sykehusveien 23
9019, Tromsø
+47 77 64 89 00
http://www.arcticzymes.com
Group companies
| Name | Category and Sector |
|---|---|
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. |
Pharmaceuticals: Major
|
ArcticZymes AS
 ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The private company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. |
Medical Specialties
|
Sector
Sales per Business
Sales per region
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.69% | 108M | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- AZT Stock
- Company ArcticZymes Technologies ASA